Free tool
FAERS Monitor: Rexulti
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205422 or its brand name (Rexulti, Brexpiprazole). Reports on generic versions are filed under their own applications.
Reports
16,890
Serious
7,192
43% of reports
Hospitalization
2,240
Death reported
1,179
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- weight increased1,712
- product use in unapproved indication1,400
- off label use1,172
- drug ineffective984
- akathisia880
- tremor662
- anxiety629
- death603
- tardive dyskinesia603
- depression598
- suicidal ideation595
- product use issue516
- insomnia513
- fatigue512
- feeling abnormal484
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 229 |
| 2016 | 2,107 |
| 2017 | 1,551 |
| 2018 | 1,417 |
| 2019 | 1,701 |
| 2020 | 1,423 |
| 2021 | 1,433 |
| 2022 | 1,328 |
| 2023 | 1,446 |
| 2024 | 1,781 |
| 2025 | 1,372 |
| 2026 | 1,100 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,037,269 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| akathisiaSignal | 880 | 85.8 | 80.2 | 68,945 |
| tardive dyskinesiaSignal | 603 | 27.2 | 25.1 | 14,873 |
| weight increasedSignal | 1,712 | 9.6 | 9.2 | 13,197 |
| suicidal ideationSignal | 595 | 8.1 | 7.5 | 3,712 |
| product use in unapproved indicationSignal | 1,400 | 7.1 | 6.7 | 7,333 |
| tremorSignal | 662 | 5.0 | 4.6 | 2,112 |
| product use issueSignal | 516 | 3.4 | 3.1 | 889 |
| depressionSignal | 598 | 3.3 | 3.0 | 953 |
| anxietySignal | 629 | 2.8 | 2.6 | 710 |
| feeling abnormalSignal | 484 | 2.5 | 2.3 | 446 |
| insomniaSignal | 513 | 2.4 | 2.2 | 423 |
| off label use | 1,172 | 1.7 | 1.6 | 326 |
| drug ineffective | 984 | 0.9 | 0.9 | 5 |
| death | 603 | 0.9 | 0.8 | 12 |
| fatigue | 512 | 0.8 | 0.8 | 21 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.